
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is a promising company with a strong track record in developing innovative ADC treatments for cancer and autoimmune disorders. The company's proprietary XpressCF platform and next-generation protein therapeutics show great potential for success. With a strong financial position and continued progress in the clinic, Sutro Biopharma is well-positioned for future growth and success in the healthcare industry.
Bears say
Sutro Biopharma is expected to face competitive challenges in the ADC market due to the consistent, customizable, and tunable features of its proprietary cell-free protein synthesis platform, leading to a presumed premium of $11.26/share for its pipeline. Additionally, STRO-004's β-glu linker with site-specific conjugation and tumor-selective cleavage is projected to improve linker stability and tumor microenvironment targeting, potentially driving higher response rates. However, KOLs have emphasized that linker stability is the key determinant of ADC efficacy and safety, indicating potential risk for Sutro's DAR8 benefit.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares